Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas.

Autor: Gile JJ; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., McGarrah PW; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Leventakos K; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Sonbol MB; Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona, USA., Starr JS; Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida, USA., Eiring RA; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Hobday TJ; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Halfdanarson TR; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk: angličtina
Zdroj: Journal of neuroendocrinology [J Neuroendocrinol] 2023 May; Vol. 35 (5), pp. e13283. Date of Electronic Publication: 2023 May 25.
DOI: 10.1111/jne.13283
Abstrakt: Poorly differentiated extrapulmonary neuroendocrine carcinomas (EP NECs) are aggressive cancers characterized by a high Ki-67 index, rapid tumor growth and poor survival, and are subdivided into small and large cell carcinoma. For small cell carcinoma of the lung, a pulmonary NEC, the combination of cytotoxic chemotherapy (CTX) and a checkpoint inhibitor (CPI) is considered standard therapy and superior to CTX alone. EP NECs are typically treated with platinum-based regimens, some clinicians have adopted the addition of a CPI to CTX based on data from trials in patients with small cell carcinoma of the lung. In this retrospective study of EP NECs, we report 38 patients treated with standard first-line CTX and 19 patients treated with CTX plus CPI. We did not observe any additional benefit of adding CPI to CTX in this cohort.
(© 2023 British Society for Neuroendocrinology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje